Cognition Therapeutics Inc (CGTX)

08:27 AM

Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

08:27 AM

Apr 03, 2026

CGTX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 03, 2026

Apr 02, 2026

CGTX Should I Buy - Intellectia AI

Apr 02, 2026

Apr 01, 2026

Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia

Apr 01, 2026

Mar 31, 2026

Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com

Mar 31, 2026

Mar 31, 2026

Cognition Therapeutics CEO Issues Letter to Shareholders - Yahoo Finance

Mar 31, 2026

Mar 30, 2026

Q1 Earnings Forecast for CGTX Issued By HC Wainwright - marketbeat.com

Mar 30, 2026

Mar 28, 2026

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm

Mar 28, 2026

Mar 27, 2026

Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2026

Mar 27, 2026

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com

Mar 27, 2026

Mar 27, 2026

Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat

Mar 27, 2026

Mar 27, 2026

Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa

Mar 27, 2026

Mar 26, 2026

Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - Minichart

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat

Mar 26, 2026

Mar 26, 2026

Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Mar 26, 2026

Mar 26, 2026

Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses - Investing.com

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 26, 2026

Mar 26, 2026

CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView

Mar 26, 2026

Mar 26, 2026

Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses By Investing.com - Investing.com South Africa

Mar 26, 2026

Mar 26, 2026

CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial - Investing.com

Mar 26, 2026

Mar 26, 2026

COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView

Mar 26, 2026

Mar 26, 2026

Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - stocktitan.net

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - The Manila Times

Mar 26, 2026

Mar 26, 2026

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record

Mar 26, 2026

Mar 25, 2026

Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - marketbeat.com

Mar 25, 2026

Mar 24, 2026

Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Mar 24, 2026

Mar 24, 2026

Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - NeurologyLive

Mar 24, 2026

Mar 23, 2026

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail

Mar 23, 2026

Mar 18, 2026

Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa

Mar 18, 2026

Mar 17, 2026

CGTX PE Ratio & Valuation, Is CGTX Overvalued - intellectia.ai

Mar 17, 2026

Mar 17, 2026

Cognition presents data on dementia drug zervimesine at conference - Investing.com

Mar 17, 2026

Mar 17, 2026

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget

Mar 17, 2026

Mar 17, 2026

Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative

Mar 17, 2026

Mar 17, 2026

Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire

Mar 17, 2026

Mar 13, 2026

Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 13, 2026

Mar 11, 2026

Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn

Mar 11, 2026

Mar 06, 2026

MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 06, 2026

Mar 02, 2026

Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia

Mar 02, 2026

Mar 02, 2026

Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria

Mar 02, 2026

Mar 02, 2026

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 02, 2026

Mar 02, 2026

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget

Mar 02, 2026

Mar 02, 2026

Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks

Mar 02, 2026